Evercore ISI Initiated TG Therapeutics Inc. [TGTX]. What else is Wall St. saying?



TG Therapeutics Inc. [NASDAQ: TGTX] traded at a high on 08/06/20, posting a 0.14 gain after which it closed the day’ session at $20.80. The company report on August 6, 2020 that TG Therapeutics to Host Conference Call on Second Quarter 2020 Financial Results and Business Update.

Investor Conference Call to be held Monday, August 10, 2020 at 8:30 AM ET.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday August 10, 2020 at 8:30 AM ET to discuss results for the second quarter of 2020 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.

The results of the trading session contributed to over 1069565 shares changing hands. Over the past one week, the price volatility of TG Therapeutics Inc. stands at 5.46% while the volatility over the past one month is 5.78%.

The market cap for TGTX stock reached $2.55 billion, with 105.46 million shares outstanding and 84.68 million shares in the current float. Compared to the average trading volume of 2.03M shares, TGTX reached a trading volume of 1069565 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about TG Therapeutics Inc. [TGTX]?

Evercore ISI have made an estimate for TG Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 05, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $20 to $24. The new note on the price target was released on January 17, 2020, representing the official price target for TG Therapeutics Inc. stock. Previously, the target price had yet another raise to $12, while B. Riley FBR analysts kept a Buy rating on TGTX stock.

The Average True Range (ATR) for TG Therapeutics Inc. is set at 1.24, with the Price to Sales ratio for TGTX stock in the period of the last 12 months amounting to 12742.08.

How has TGTX stock performed recently?

TG Therapeutics Inc. [TGTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.00. With this latest performance, TGTX shares dropped by -12.82% in over the last four-week period, additionally plugging by 31.40% over the last 6 months – not to mention a rise of 212.78% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TGTX stock in for the last two-week period is set at 50.15, with the RSI for the last a single of trading hit 49.15, and the three-weeks RSI is set at 51.74 for TG Therapeutics Inc. [TGTX]. The present Moving Average for the last 50 days of trading for this stock 20.06, while it was recorded at 20.47 for the last single week of trading, and 13.83 for the last 200 days.

TG Therapeutics Inc. [TGTX]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and TG Therapeutics Inc. [TGTX] shares currently have an operating margin of -112009.87. TG Therapeutics Inc.’s Net Margin is presently recorded at -113730.92.

Return on Total Capital for TGTX is now -328.32, given the latest momentum, and Return on Invested Capital for the company is -339.50. Return on Equity for this stock declined to -551.85, with Return on Assets sitting at -140.19. When it comes to the capital structure of this company, TG Therapeutics Inc. [TGTX] has a Total Debt to Total Equity ratio set at 106.16. Additionally, TGTX Total Debt to Total Capital is recorded at 51.49, with Total Debt to Total Assets ending up at 25.15. Long-Term Debt to Equity for the company is recorded at 101.48, with the Long-Term Debt to Total Capital now at 49.23.

Reflecting on the efficiency of the workforce at the company, TG Therapeutics Inc. [TGTX] managed to generate an average of -$1,290,082 per employee. Receivables Turnover for the company is 3.20 with a Total Asset Turnover recorded at a value of 0.00.TG Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.40.

Earnings analysis for TG Therapeutics Inc. [TGTX]

With the latest financial reports released by the company, TG Therapeutics Inc. posted -0.42/share EPS, while the average EPS was predicted by analysts to be reported at -0.41/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -2.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TGTX.

Insider trade positions for TG Therapeutics Inc. [TGTX]

There are presently around $1,313 million, or 61.20% of TGTX stock, in the hands of institutional investors. The top three institutional holders of TGTX stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 10,387,411, which is approximately 5.132% of the company’s market cap and around 1.20% of the total institutional ownership; FMR LLC, holding 9,523,241 shares of the stock with an approximate value of $198.08 million in TGTX stocks shares; and BLACKROCK INC., currently with $126.95 million in TGTX stock with ownership of nearly 1.238% of the company’s market capitalization.

Positions in TG Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 86 institutional holders increased their position in TG Therapeutics Inc. [NASDAQ:TGTX] by around 17,985,709 shares. Additionally, 71 investors decreased positions by around 7,544,915 shares, while 23 investors held positions by with 37,594,898 shares. The mentioned changes placed institutional holdings at 63,125,522 shares, according to the latest SEC report filing. TGTX stock had 39 new institutional investments in for a total of 3,684,972 shares, while 23 institutional investors sold positions of 1,074,461 shares during the same period.



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam